251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Cooperations and alliances<br />
At all stages of the research-intensive biotechnology sector,<br />
cooperations between companies and between companies<br />
and research institutes are indispensable for the establishment<br />
of a sustainable value added chain.<br />
Thanks to the excellent research facilities and university<br />
institutes, the locations in the Bavarian <strong>Biotech</strong>nology<br />
Cluster therefore find themselves in a privileged position<br />
that is also recognised internationally.<br />
COOPERATIONS AND DEALS 2007<br />
Cooperation Partner<br />
Cambridge Antibody Technology<br />
Johnson & Johnson<br />
Bayer Schering Pharma AG<br />
Palau Pharma (Barcelona, Spain)<br />
Molecular Connections (Bangalore, India)<br />
Tracon Pharmaceuticals<br />
Astellas<br />
Nycomed<br />
Boehringer Ingelheim Pharmaceuticals, Inc.<br />
Genfit (Lille, France)<br />
Alpharma<br />
Boehringer Ingelheim Pharmaceuticals, Inc.<br />
Dyax<br />
Novartis<br />
Operon <strong>Biotech</strong>nologies<br />
Announcement<br />
of Cooperation<br />
Jan 07<br />
Jan 07<br />
Jan 07<br />
Jan 07<br />
Jan 07<br />
Mar 07<br />
Mar 07<br />
May 07<br />
Jun 07<br />
Jul 07<br />
Sep 07<br />
Oct 07<br />
Nov 07<br />
Dec 07<br />
Dec 07<br />
Type of Cooperation<br />
A selection from the large number of cooperations among<br />
companies can be found in the following list:<br />
License agreement to develop and commercialize the antibody SC-1 (first identified by<br />
Oncomab GMBH/Patrys Ltd. and in-licensed by The Debiopharm Group in 2003)<br />
Kinaxo enters agreement to carry out selectivity analyses for selected J&J small molecule<br />
compounds<br />
Bayer Schering Pharma AG selects CRELUX as structural biology service provider to deliver<br />
several complex structures on three different targets.<br />
Affectis in-licenses a clinical stage compound for the treatment of psychiatric disorders<br />
from Palau Pharma.<br />
Genomatix and Molecular Connections form strategic partnership.<br />
Agreement granting TRACON exclusive worldwide rights to develop and commercialize<br />
Micromet's D93 antibody with a novel mode of action for the treatment of cancer.<br />
MorphoSys entered into a license agreement for the use of its HuCAL technology. It is the<br />
third therapeutic agreement of MorphoSys in Japan.<br />
Micromet and Nycomed enter into exclusive worldwide collaboration to develop and<br />
commercialize anti-GM-CSF antibodies for the treatment of inflammatory and autoimmune<br />
diseases.<br />
Proteros enters into a research collaboration with Boehringer Ingelheim in the field of protein<br />
crystallographygehen.<br />
Bicoll signs a partnership with Genfit and announces the partial financing of a 3.2 million<br />
euro joint EuroTrans-Bio project by ERA-Net/ European Commission.<br />
IDEA signs major licensing agreement with Alpharma for Diractin®, a treatment of deep<br />
pain.<br />
Biomax licenses the BioRS Integration and Retrieval System to Boehringer Ingelheim.<br />
MorphoSys und Dyax sign a licensing agreement covering a patent portfolio relating to<br />
antibodies and other proteins.<br />
MorphoSys and Novartis forge strategic alliance to establish an innovative therapeutic<br />
antibody pipeline.<br />
Operon and MWG (all part of the Eurofins Genomics network) agree to work together in<br />
order to create a new worldwide leader in the competitive custom oligonucleotide market.<br />
17
Change language